Aldeyra Therapeutics, Inc.
ALDX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001341235
In the last 90 days, Aldeyra Therapeutics, Inc. insiders filed 3 open-market purchases and 0 sales; 107 institutions reported holding it in 13F filings for Q2 2026, worth $77.7M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 17, 2026
- $41.9M
- Insider buysLast 90 days, $140.3K in total
- 3
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −19 vs. previous quarter
- 107
- 13F valueReported value at the end of Q2 2026
- $77.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$33.8M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.16M
- Shares sold short
- Change
- −26.8K
- −0.8% vs. previous
- Days to cover
- 3.44
- At average daily volume
Superinvestors holding ALDX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ALDX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Aldeyra Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 (view filing)5:33 PM ET | Nov 12 | 4 days | Deptula-Hicks Darlene MDirector | PPurchase | +7.50K | $0.65 | +$4.88K | New position7.50K after | |
| Nov 13, 2026 (view filing)4:31 PM ET | Nov 11 | 2 days | Alfieri MichaelPrincipal Financial Officer | PPurchase | +10.0K | $0.65 | +$6.50K | +133.3%17.5K after | |
| Nov 13, 2026 (view filing)4:26 PM ET | Nov 11 | 2 days | Douglas RichardDirector | PPurchase | +200.0K | $0.6445 | +$128.9K | +102.6%395.0K after | |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Brady Todd CPresident and CEO | PPurchase | +250.0K | $1.67 | +$417.5K | +17.0%1.72M after | |
| Mar 20, 2026 (view filing) | Mar 19 | 1 day | Douglas RichardDirector | PPurchase | +70.0K | $1.40 | +$98.0K | +56.0%195.0K after | |
| Mar 19, 2026 (view filing) | Mar 18 | 1 day | Alfieri MichaelPrincipal Financial Officer | PPurchase | +5.00K | $1.42 | +$7.10K | +200.0%7.50K after | |
| Aug 15, 2025 (view filing) | Aug 13 | 2 days | Alfieri MichaelPrincipal Financial Officer | PPurchase | +2.50K | $5.30 | +$13.3K | New position2.50K after | |
| Aug 13, 2025 (view filing) | Aug 11 | 2 days | Machatha StephenChief Development Officer | SSale | −22.1K | $5.15 | −$113.7K | −9.1%221.8K after | |
| Apr 7, 2025 (view filing)6:43 PM ET | Apr 3 | 4 days | Edelman Joseph and 2 others10% Owner | SSale | −3.40M | $1.42 | −$4.83M | −36.7%5.88M after | |
| Oct 21, 2024 (view filing) | May 3, 2021-Apr 12, 2023 | 1,267 daysLate | Miller-Rich NancyDirector | PPurchase | +922 | $11.33 | +$10.4K | New position922 after | 2 lots |
Top 10 13F holders, Q2 2026
See all 107 holdersThe largest institutional positions in Aldeyra Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 5,475,516 | $11.7M | 5.59% | 00.0% | Unchanged |
| AQR Capital Management LLC | 3,751,558 | $7.99M | 0.00% | +921,683+32.6% | Added |
| Kingdon Capital Management, L.L.C. | 2,652,315 | $5.65M | 0.76% | +500,000+23.2% | Added |
| Vanguard Capital Management LLC | 2,361,796 | $5.03M | 0.00% | −1,946−0.1% | Reduced |
| D. E. Shaw & Co., Inc. | 1,940,338 | $4.13M | 0.00% | +536,348+38.2% | Added |
| Marshall Wace, LLP | 1,506,974 | $3.21M | 0.00% | +1,377,281+1,062.0% | Added |
| 683 Capital Management, LLC | 1,450,000 | $3.09M | 0.28% | −50,000−3.3% | Reduced |
| Jane Street Group, LLC | 1,375,115 | $2.93M | 0.00% | +406,224+41.9% | Added |
| BlackRock, Inc. | 1,257,243 | $2.68M | 0.00% | −2,506,644−66.6% | Reduced |
| Qube Research & Technologies Ltd | 1,128,803 | $2.40M | 0.00% | +1,041,725+1,196.3% | Added |
Holders of 5% or more of ALDX
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Aldeyra Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Barclays PLC | 13G | 5.48%3.31M shares | New | Nov 6, 20261 filing | Nov 6, 2026 | SEC |